Data from: One and two year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource

Objectives: To analyse treatment outcomes and share clinical data from a
large, single-center, well-curated database (8174 eyes / 6664 patients
with 120,756 single entries) of patients with neovascular age related
macular degeneration (AMD) treated with anti-vascular endothelial growth
factor (VEGF). By making our depersonalised raw data openly available, we
aim to stimulate further research in AMD, as well as setting a precedent
for future work in this area. Setting: Retrospective, comparative,
non-randomised electronic medical record (EMR) database cohort study of
the UK Moorfields AMD database with data extracted between 2008 and 2018.
Participants: Including one eye per patient, 3357 eyes/patients (61%
female). Extraction criteria were ≥ 1 ranibizumab or aflibercept
injection, entry of “AMD” in the diagnosis field of the EMR, and a minimum
of one year of follow-up. Exclusion criteria were unknown date of first
injection and treatment outside of routine clinical care at Moorfields
before the first recorded injection in the database. Main outcome
measures: Primary outcome measure was change in VA at one and two years
from baseline as measured in Early Treatment Diabetic Retinopathy Study
(ETDRS) letters. Secondary outcomes were the number of injections and
predictive factors for VA gain. Results: Mean VA gain at one-year and two
years were +5.5 (95%CI:5.0,6.0) and +4.9 (95%CI:4.2,5.6) letters
respectively. Fifty-four percent of eyes gained ≥5 letters at two years,
63% had stable VA (±≤14 letters), forty-four percent of eyes maintained
good VA (≥70 letters). Patients received a mean of 7.7 (95%CI:7.6,7.8)
injections during year one and 13.0 (95%CI:12.8,13.2) injections over two
years. Younger age, lower baseline VA, and more injections were associated
with higher VA gain at two years. Conclusion: This study benchmarks high
quality EMR study results of real life AMD treatment and promotes open
science in clinical AMD research by making the underlying data publicly
available.